Radiation plus immunotherapy and chemo before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75 with newly diagnosed breast cancer that has not been treated yet.
- Your cancer must be triple-negative (ER/PR negative, HER2 negative) and at an early or locally advanced stage (stage II or III).
- You must be in good general health, with an ECOG performance status of 0 or 1 (able to carry on normal activities).
- You must have measurable tumors that can be assessed by imaging.
- You must be willing to undergo radiation therapy and surgery as part of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests a combination of a PD-L1 antibody (a type of immunotherapy) with a low-dose, continuous chemotherapy regimen called VEX for advanced triple-negative breast cancer that has spread to other parts of the body. It may be an option if you have had only one prior chemotherapy for metastatic disease and have already been treated with certain common chemo drugs.
This study tests a combination of chemotherapy and immunotherapy given before surgery for triple-negative breast cancer. It aims to shrink the tumor and improve outcomes. The treatment is given intravenously.
This trial tests if adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery can improve outcomes for women with early or locally advanced triple-negative breast cancer. It is for those who haven't had treatment yet and are candidates for surgery.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
Hear when a new Stereotactic Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.